Biogen, Elan MS Drug May Return

Biogen, Elan MS Drug May Return, Its Promise Cut, Analysts Say
March 3, 2005 05:22 EST -- Biogen Idec Inc. and Elan Corp.'s multiple sclerosis drug Tysabri may return to the market with restrictions that will limit its sales to less than half the $4 billion once expected, Merrill Lynch & Co. analyst Erica Whittaker said.